http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-724413-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a57036e4339d4d44cbb4ccce6c175cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9f5859292d9c411d7578172ba0b2dd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_843dc59c4a56987ada944268b7e513a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7cbdaaf8e6173e3949e979b4a99b6f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96320572a58e25274fc84bbb44122580 |
| publicationDate | 2021-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-724413-A |
| titleOfInvention | Methods of reducing basophil levels |
| abstract | Disclosed is the use of a monoclonal, chimeric, humanised or human antibody that binds IL-5R in the manufacture of a medicament for treating or preventing an basophil mediated disease or disorder in a human subject, wherein said antibody is parenterally administered to said subject between about 0.001 to about 100 mg/kg, and wherein said antibody comprises an immunoglobulin Fc region comprising no fucose, and wherein the administration of the antibody reduces the number of peripheral blood basophils from the human subject’s circulation. |
| priorityDate | 2007-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1486.